Modality
Bispecific Ab
MOA
IL-17i
Target
FXIa
Pathway
Notch
RCCGAEndometrial Ca
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
Aug 2021
→ Mar 2030
Phase 1Current
NCT03789072
1,746 pts·RCC
2021-08→2030-03·Terminated
1,746 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-234.0y awayInterim· RCC
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Termina…
Catalysts
Interim
2030-03-23 · 4.0y away
RCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03789072 | Phase 1 | RCC | Terminated | 1746 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |